Download PDF
Am J Perinatol 2023; 40(06): 602-611
DOI: 10.1055/s-0041-1739427
Clinical Opinion

Indicated Opioids in Pregnancy: Guidance on Providing Comprehensive Care

Erin M. Cleary 
1   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, Ohio
,
Marcela C. Smid 
2   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City, Utah
,
Christina Bokat
3   Department of Anesthesia, University of Utah Health, Salt Lake City, Utah
,
Maged M. Costantine 
1   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, Ohio
,
Kara M. Rood
1   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, Ohio
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

In modern obstetric practice, providers will encounter patients for whom opioid use in pregnancy is reasonable or even necessary. A “one-size-fits-all” approach to the counseling and management of such patients is misguided. Understanding indications for ongoing opioid use in pregnancy is essential to patient-centered care. Specifically, recognition of the nuanced differences between opioid dependence and opioid use disorder is crucial for appropriate diagnosis, screening for common concurrent conditions, adequately counseling about individualized maternal and perinatal risks, and accurate documentation of diagnoses and medical decision-making. In this paper, we explore the current typical scenarios in which opioid use in pregnancy may be encountered, ongoing opioid prescribing should be considered, and provide a guide for the obstetric provider to navigate the antepartum, intrapartum, and postpartum periods.

Key Points

  • Opioid use in pregnant and postpartum individuals is not rare.

  • Obstetric providers may elect to assume opioid prescribing.

  • Obstetric providers are positioned to optimize outcomes for the mother–infant dyad.

Keywords

opioid use disorder - opioid dependency - prenatal care - pain management

Note

The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.




Publication History

Received: 16 May 2021

Accepted: 04 October 2021

Article published online:
12 November 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Ko JY, D'Angelo DV, Haight SC. et al. Vital signs: prescription opioid pain reliever use during pregnancy - 34 U.S. Jurisdictions, 2019. MMWR Morb Mortal Wkly Rep 2020; 69 (28) 897-903
    CrossrefPubMedGoogle Scholar
  • 2 Centers for Disease Control and Prevention. National Center for Injury Prevention Control, Division of Unintentional Injury. Prescription Painkiller Overdoses. Accessed October 26, 2021 at: https://www.cdc.gov/drugoverdose/pdf/policyimpact-prescriptionpainkillerod-a.pdf
    PubMedGoogle Scholar
  • 3 Kozhimannil KB, Graves AJ, Jarlenski M, Kennedy-Hendricks A, Gollust S, Barry CL. Non-medical opioid use and sources of opioids among pregnant and non-pregnant reproductive-aged women. Drug Alcohol Depend 2017; 174: 201-208
    CrossrefPubMedGoogle Scholar
  • 4 American Psychiatric Association. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 5th ed.. 2013. Arlington, VA
    CrossrefGoogle Scholar
  • 5 ACOG CREOG. Opiate use disorder. Accessed October 26, 2021 at: https://www.acog.org/education-and-events/creog/curriculum-resources/additional-curricular-resources/opiate-use-disorder
    PubMedGoogle Scholar
  • 6 Volkow N, Li TK. The neuroscience of addiction. Nat Neurosci 2005; 8 (11) 1429-1430 DOI: 10.1038/nn1105-1429.
    CrossrefPubMedGoogle Scholar
  • 7 Bechara A, Berridge KC, Bickel WK, Morón JA, Williams SB, Stein JS. A neurobehavioral approach to addiction: implications for the opioid epidemic and the psychology of addiction. Psychol Sci Public Interest 2019; 20 (02) 96-127
    CrossrefPubMedGoogle Scholar
  • 8 Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008; 9 (04) 444-459
    CrossrefPubMedGoogle Scholar
  • 9 Chen Q, Larochelle MR, Weaver DT. et al. Prevention of prescription opioid misuse and projected overdose deaths in the United States. JAMA Netw Open 2019; 2 (02) e187621
    CrossrefPubMedGoogle Scholar
  • 10 Wilson N, Kariisa M, Seth P, Smith IV H, Davis NL. Drug and opioid-involved overdose deaths - United States, 2017-2018. MMWR Morb Mortal Wkly Rep 2020; 69 (11) 290-297
    CrossrefPubMedGoogle Scholar
  • 11 Haight SC, Ko JY, Tong VT, Bohm MK, Callaghan WM. Opioid use disorder documented at delivery hospitalization - United States, 1999-2014. MMWR Morb Mortal Wkly Rep 2018; 67 (31) 845-849
    CrossrefPubMedGoogle Scholar
  • 12 Hall OT, Hall OE, McGrath RP, Haile ZT. Years of life lost due to opioid overdose in Ohio. J Addict Med 2019
    PubMedGoogle Scholar
  • 13 Prasad M, Jones M. Medical complications of opioid use disorder in pregnancy. Semin Perinatol 2019; 43 (03) 162-167
    CrossrefPubMedGoogle Scholar
  • 14 Maeda A, Bateman BT, Clancy CR, Creanga AA, Leffert LR. Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes. Anesthesiology 2014; 121 (06) 1158-1165
    CrossrefPubMedGoogle Scholar
  • 15 Larson JJ, Graham DL, Singer LT. et al. Cognitive and behavioral impact on children exposed to opioids during pregnancy. Pediatrics 2019; 144 (02) e20190514
    CrossrefPubMedGoogle Scholar
  • 16 Jarlenski MP, Krans EE, Kim JY. et al. Five-year outcomes among medicaid-enrolled children with in utero opioid exposure. Health Aff (Millwood) 2020; 39 (02) 247-255
    CrossrefPubMedGoogle Scholar
  • 17 Committee opinion no. 711: opioid use and opioid use disorder in pregnancy. Obstet Gynecol 2017; 130 (02) e81-e94
    CrossrefPubMedGoogle Scholar
  • 18 Chasnoff IJ, McGourty RF, Bailey GW. et al. The 4P's Plus screen for substance use in pregnancy: clinical application and outcomes. J Perinatol 2005; 25 (06) 368-374
    CrossrefPubMedGoogle Scholar
  • 19 Coleman-Cowger VH, Oga EA, Peters EN, Trocin KE, Koszowski B, Mark K. Accuracy of three screening tools for prenatal substance use. Obstet Gynecol 2019; 133 (05) 952-961
    CrossrefPubMedGoogle Scholar
  • 20 Jones HE, Fischer G, Heil SH. et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER)–approach, issues and lessons learned. Addiction 2012; 107 (Suppl. 01) 28-35
    CrossrefPubMedGoogle Scholar
  • 21 Jones HE, Kaltenbach K, Heil SH. et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363 (24) 2320-2331
    CrossrefPubMedGoogle Scholar
  • 22 Jones HE, Johnson RE, Jasinski DR, Milio L. Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone. Drug Alcohol Depend 2005; 78 (01) 33-38
    CrossrefPubMedGoogle Scholar
  • 23 Link HM, Jones H, Miller L, Kaltenbach K, Seligman N. Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis. Am J Obstet Gynecol MFM 2020; 2 (03) 100179
    CrossrefPubMedGoogle Scholar
  • 24 Lappen JR, Stark S, Bailit JL, Gibson KS. Delivery dose of methadone, but not buprenorphine, is associated with the risk and severity of neonatal opiate withdrawal syndrome. Am J Obstet Gynecol MFM 2020; 2 (01) 100075
    CrossrefPubMedGoogle Scholar
  • 25 Caritis SN, Bastian JR, Zhang H. et al. An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy. Am J Obstet Gynecol 2017; 217 (04) 459.e1-459.e6
    CrossrefPubMedGoogle Scholar
  • 26 Coulson CC, Lorencz E, Rittenhouse K, Ramage M, Lorenz K, Galvin SL. Association of maternal buprenorphine or methadone dose with fetal growth indices and neonatal abstinence syndrome. Am J Perinatol 2021; 38 (01) 28-36
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Zhang H, Kalluri HV, Bastian JR. et al. Gestational changes in buprenorphine exposure: a physiologically-based pharmacokinetic analysis. Br J Clin Pharmacol 2018; 84 (09) 2075-2087
    CrossrefPubMedGoogle Scholar
  • 28 Cleary EM, Byron RK, Hinely KA, Talley AW, Costantine MM, Rood KM. Subcutaneous buprenorphine extended-release use among pregnant and postpartum women. Obstet Gynecol 2020; 136 (05) 902-903
    CrossrefPubMedGoogle Scholar
  • 29 Zedler BK, Mann AL, Kim MM. et al. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction 2016; 111 (12) 2115-2128
    CrossrefPubMedGoogle Scholar
  • 30 Jones HE, Martin PR, Heil SH. et al. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat 2008; 35 (03) 245-259
    CrossrefPubMedGoogle Scholar
  • 31 ASAM. ASAM announces partnership with ACOG to provide waiver qualifying course on treatment for opioid use disorders. Accessed October 26, 2021 at: https://www.asam.org/Quality-Science/publications/magazine/read/article/2020/02/28/asam-announces-partnership-with-the-acog-to-provide-waiver-qualifying-course-on-treatment-for-opioid-use-disorders
    PubMedGoogle Scholar
  • 32 Woods GT, Lim SL, Salinaro JR. Strengthening opioid use disorder training among obstetrician-gynecologists: Hollander et al's call to action. Am J Obstet Gynecol 2019; 221 (05) 533
    CrossrefPubMedGoogle Scholar
  • 33 Critchfield AS, Hansen WF. The opioid crisis: prenatal and postnatal care Recent. Contemp Ob Gyn Published online 2018.
    PubMedGoogle Scholar
  • 34 Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: National Academies Press (US); 2011
    Google Scholar
  • 35 Nugraha B, Gutenbrunner C, Barke A. et al; IASP Taskforce for the Classification of Chronic Pain. The IASP classification of chronic pain for ICD-11: functioning properties of chronic pain. Pain 2019; 160 (01) 88-94
    CrossrefPubMedGoogle Scholar
  • 36 Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. JAMA 2016; 65 (01) 1-49
    PubMedGoogle Scholar
  • 37 Smid MC, Stone NM, Baksh L. et al. Pregnancy-associated death in utah: contribution of drug-induced deaths. Obstet Gynecol 2019; 133 (06) 1131-1140
    CrossrefPubMedGoogle Scholar
  • 38 Bateman BT, Franklin JM, Bykov K. et al. Persistent opioid use following cesarean delivery: patterns and predictors among opioid-naïve women. Am J Obstet Gynecol 2016; 215 (03) 353.e1-353.e18
    CrossrefPubMedGoogle Scholar
  • 39 Osmundson SS, Wiese AD, Min JY. et al. Delivery type, opioid prescribing, and the risk of persistent opioid use after delivery. Am J Obstet Gynecol 2019; 220 (04) 405-407
    CrossrefPubMedGoogle Scholar
  • 40 Peahl AF, Dalton VK, Montgomery JR, Lai YL, Hu HM, Waljee JF. Rates of new persistent opioid use after vaginal or cesarean birth among US women. JAMA Netw Open 2019; 2 (07) e197863
    CrossrefPubMedGoogle Scholar
  • 41 Peahl AF, Morgan DM, Dalton VK. et al. New persistent opioid use after acute opioid prescribing in pregnancy: a nationwide analysis. Am J Obstet Gynecol 2020; 223 (04) 566.e1-566.e13
    CrossrefPubMedGoogle Scholar
  • 42 Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10 (04) 287-333
    CrossrefPubMedGoogle Scholar
  • 43 Blyth FM, March LM, Nicholas MK, Cousins MJ. Chronic pain, work performance and litigation. Pain 2003; 103 (1,2): 41-47
    CrossrefPubMedGoogle Scholar
  • 44 Mills SEE, Nicolson KP, Smith BH. Chronic pain: a review of its epidemiology and associated factors in population-based studies. Br J Anaesth 2019; 123 (02) e273-e283
    CrossrefPubMedGoogle Scholar
  • 45 Gatchel RJ, Okifuji A. Evidence-based scientific data documenting the treatment and cost-effectiveness of comprehensive pain programs for chronic nonmalignant pain. J Pain 2006; 7 (11) 779-793
    CrossrefPubMedGoogle Scholar
  • 46 Strang J, Volkow ND, Degenhardt L. et al. Opioid use disorder. Nat Rev Dis Prim 2020; 7 (11) 779-793
    PubMedGoogle Scholar
  • 47 Venkatesh KK, Pate V, Boggess KA, Jones HE, Funk MJ, Smid MC. Trends in opioid and psychotropic prescription in pregnancy in the United States from 2001 to 2015 in a privately insured population : a cross-sectional study. Ann Intern Med 2020; 173 (11, suppl): S19-S28
    CrossrefPubMedGoogle Scholar
  • 48 Adewumi AD, Hollingworth SA, Maravilla JC, Connor JP, Alati R. Prescribed dose of opioids and overdose: a systematic review and meta-analysis of unintentional prescription opioid overdose. CNS Drugs 2018; 32 (02) 101-116
    CrossrefPubMedGoogle Scholar
  • 49 Jones CM, McAninch JK. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. Am J Prev Med 2015; 49 (04) 493-501
    CrossrefPubMedGoogle Scholar
  • 50 White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction 1999; 94 (07) 961-972
    CrossrefPubMedGoogle Scholar
  • 51 Academy of Perinatal Harm Reduction. . Accessed October 26, 2021 at: https://www.perinatalharmreduction.org/
    PubMedGoogle Scholar
  • 52 Bateman BT, Hernandez-Diaz S, Rathmell JP. et al. Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States. Anesthesiology 2014; 120 (05) 1216-1224
    CrossrefPubMedGoogle Scholar
  • 53 Zaghw A, Koronfel M, Podgorski E. et al. Pain management for pregnant women in the opioid crisis era. In: Pain Management in Special Circumstances. IntechOpen. 2018
    CrossrefGoogle Scholar
  • 54 Vas J, Cintado MC, Aranda-Regules JM, Aguilar I, Rivas Ruiz F. Effect of ear acupuncture on pregnancy-related pain in the lower back and posterior pelvic girdle: A multicenter randomized clinical trial. Acta Obstet Gynecol Scand 2019; 98 (10) 1307-1317
    CrossrefPubMedGoogle Scholar
  • 55 Li DK, Ferber JR, Odouli R, Quesenberry C. Use of nonsteroidal antiinflammatory drugs during pregnancy and the risk of miscarriage. Am J Obstet Gynecol 2018; 219 (03) 275.e1-275.e8
    CrossrefPubMedGoogle Scholar
  • 56 Nakhai-Pour HR, Bérard A. Major malformations after first trimester exposure to aspirin and NSAIDs. Expert Rev Clin Pharmacol 2008; 1 (05) 605-616
    CrossrefPubMedGoogle Scholar
  • 57 Koren G, Florescu A, Costei AM, Boskovic R, Moretti ME. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother 2006; 40 (05) 824-829
    CrossrefPubMedGoogle Scholar
  • 58 Martin CE, Terplan M, Krans EE. Pain, opioids, and pregnancy: historical context and medical management. Clin Perinatol 2019; 46 (04) 833-847
    CrossrefPubMedGoogle Scholar
  • 59 Raymond BL, Kook BT, Richardson MG. The opioid epidemic and pregnancy: implications for anesthetic care. Curr Opin Anaesthesiol 2018; 31 (03) 243-250
    CrossrefPubMedGoogle Scholar
  • 60 ACOG committee opinion no 736: optimizing postpartum care. Obstet Gynecol 2018; 131 (05) e140-e150
    CrossrefPubMedGoogle Scholar
  • 61 Guttmacher Institute. Substance use during pregnancy. Accessed October 26, 2021 at: https://www.guttmacher.org/state-policy/explore/substance-use-during-pregnancy
    PubMedGoogle Scholar
  • 62 Committee opinion 473: substance abuse reporting and pregnancy: the role of the obstetrician-gynecologist. Obstet Gynecol 2011; 117 (01) 200-201
    CrossrefPubMedGoogle Scholar
  • 63 Committee opinion no. 633: Alcohol abuse and other substance use disorders: Ethical issues in obstetric and gynecologic practice. Obstet Gynecol 2015; 125 (06) 1529-1537
    CrossrefPubMedGoogle Scholar
  • 64 Jarlenski M, Hogan C, Bogen DL, Chang JC, Bodnar LM, Van Nostrand E. Characterization of U.S. state laws requiring health care provider reporting of perinatal substance use. Women's Heal Issues 2017; 27 (03) 264-270
    CrossrefPubMedGoogle Scholar
  • 65 Lu YE, Landsverk J, Ellis-Macleod E, Newton R, Ganger W, Johnson I. Race, ethnicity, and case outcomes in child protective services. Child Youth Serv Rev 2004; 26 (05) 447-461
    CrossrefPubMedGoogle Scholar
  • 66 About Utah crime endangerment of a child or vulnerable adult under code 76-5-112.5. Accessed October 26, 2021 at: https://www.utahcriminallaw.net/utah-crime-endangerment-child-vulnerable-adult/
    PubMedGoogle Scholar
  • 67 O'Rourke-Suchoff D, Sobel L, Holland E, Perkins R, Saia K, Bell S. The labor and birth experience of women with opioid use disorder: a qualitative study. Women Birth 2020; 33 (06) 592-597
    CrossrefPubMedGoogle Scholar
  • 68 Lind JN, Interrante JD, Ailes EC. et al. Maternal use of opioids during pregnancy and congenital malformations: a systematic review. Pediatrics 2017; 139 (06) e20164131 DOI: 10.1542/peds.2016-4131.
    CrossrefPubMedGoogle Scholar
  • 69 Bada HS, Das A, Bauer CR. et al. Low birth weight and preterm births: etiologic fraction attributable to prenatal drug exposure. J Perinatol 2005; 25 (10) 631-637
    CrossrefPubMedGoogle Scholar
  • 70 Herron A, Koehler Brennan T. American Society of Addiction Medicine. The ASAM Essentials of Addiction Medicine. 3rd ed.. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2020
    Google Scholar
  • 71 Webster L. Opioid risk tool (ORT) for narcotic abuse. Accessed September 1, 2021 at: https://www.mdcalc.com/opioid-risk-tool-ort-narcotic-abuse
    PubMedGoogle Scholar
  • 72 ACOG. Withdrawn clinical document. Accessed March 12, 2020 at: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/04/screening-for-hepatitis-c-virus-infection
    PubMedGoogle Scholar
  • 73 Ito S. Opioids in breast milk: pharmacokinetic principles and clinical implications. J Clin Pharmacol 2018; 58 (Suppl. 10) S151-S163
    CrossrefPubMedGoogle Scholar
  • 74 Timm NL. Maternal use of oxycodone resulting in opioid intoxication in her breastfed neonate. J Pediatr 2013; 162 (02) 421-422
    CrossrefPubMedGoogle Scholar
  • 75 Anderson PO, Sauberan JB, Lane JR, Rossi SS. Hydrocodone excretion into breast milk: the first two reported cases. Breastfeeding Medicine 2007; 2 (01) 10-14
    CrossrefPubMedGoogle Scholar
  • 76 Madadi P, Koren G, Cairns J. et al. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 2007; 53 (01) 33-35
    PubMedGoogle Scholar
  • 77 Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med 2015; 9 (05) 358-367
    CrossrefPubMedGoogle Scholar
  • 78 McQueen K, Murphy-Oikonen J. Neonatal abstinence syndrome. N Engl J Med 2016; 375 (25) 2468-2479
    CrossrefPubMedGoogle Scholar
  • 79 Kocherlakota P. Neonatal abstinence syndrome. Pediatrics 2014; 134 (02) e547-e561
    CrossrefPubMedGoogle Scholar
  • 80 Doherty KM, Scott TA, Morad A. et al. Evaluating definitions for neonatal abstinence syndrome. Pediatrics 2021; 147 (01) e2020007393
    CrossrefPubMedGoogle Scholar
  • 81 MacMillan KDL. Neonatal abstinence syndrome: review of epidemiology, care models, and current understanding of outcomes. Clin Perinatol 2019; 46 (04) 817-832
    CrossrefPubMedGoogle Scholar
  • 82 Maguire DJ, Taylor S, Armstrong K. et al. Long-term outcomes of infants with neonatal abstinence syndrome. Neonatal Netw 2016; 35 (05) 277-286
    CrossrefPubMedGoogle Scholar
  • 83 Become a buprenorphine waivered practitioner. SAMHSA. Accessed September 1, 2021 at: https://www.samhsa.gov/medication-assisted-treatment/become-buprenorphine-waivered-practitioner
    PubMedGoogle Scholar
  • 84 Risk Evaluation and Mitigation Strategy (REMS). Accessed September 1, 2021 at: https://www.sublocaderems.com
    PubMedGoogle Scholar
  • 85 Towers CV, Deisher H. Subcutaneous extended-release buprenorphine use in pregnancy. Case Rep Obstet Gynecol 2020; 2020: 3127676
    PubMedGoogle Scholar
  • 86 National Institute on Drug Abuse. Medication treatment for opioid-dependent expecting mothers (MOMs): a pragmatic randomized trial comparing two buprenorphine formulations (NIH HEAL initiative). Accessed September 1, 2021 at: https://www.drugabuse.gov/about-nida/organization/cctn/ctn/research-studies/medication-treatment-opioid-dependent-expecting-mothers-moms-pragmatic-randomized-trial-comparing
    PubMedGoogle Scholar
  • 87 Joudrey PJ, Edelman EJ, Wang EA. Methadone for opioid use disorder-decades of effectiveness but still miles away in the US. JAMA Psychiatry 2020; 77 (11) 1105-1106
    CrossrefPubMedGoogle Scholar